Century Therapeutics, Inc.

Century Therapeutics is headquartered in the United States and conducts most of its research, development, and manufacturing activities there. Its in-house cell therapy manufacturing facility is located in Branchburg, New Jersey, and the company also uses FUJIFILM Cellular Dynamics' cGMP facility in Madison, Wisconsin for certain clinical supply. The company received a QP declaration in February 2025 to support clinical supply from its own facility for EU studies, indicating an ability to serve both U.S. and European clinical programs. Geography matters mainly because manufacturing location, regulatory compliance, and clinical trial supply logistics directly affect development timelines and cost. The company does not disclose country-level revenue concentration in the provided excerpts, and its revenue is currently driven by collaboration arrangements rather than geographic end-market sales.

Century Therapeutics faces the classic risks of a clinical-stage biotech company: its pipeline is concentrated in a limited number of early-stage programs, and failure to advance them would materially harm the business. The company also depends on future financing and collaboration revenue, so any inability to raise capital or replace the terminated Bristol-Myers Squibb agreement would pressure operations and runway. Manufacturing execution is another key risk because cell therapy products are complex, sensitive to supply-chain handling, and dependent on cGMP compliance and process consistency. Competitive risk is high, as larger pharmaceutical companies and better-funded biotech peers may develop safer, more effective, or faster-to-market therapies, including non-cell therapy alternatives such as bispecific antibodies and T-cell engagers. Regulatory, clinical trial, and healthcare-law compliance risks are also material because approval timelines, patient enrollment, and fraud-and-abuse rules can affect both development and eventual commercialization.